Acute myocardial infarction as the initial thrombotic event of thrombotic thrombocytopenic purpura

Blood Coagulation and Fibrinolysis

Volumn 27, Issue 8, 2016, Pages 948-951

  Takimoto, Tomoko ^a   Nakao, Mitsushige ^b   Nakajo, Takuya ^b   Chinen, Yoshiaki ^a   Kuroda, Junya ^a   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Otsu Municipal Hospital   (Japan)

Author keywords

Acquired thrombotic thrombocytopenic purpura; Acute myocardial infarction; ADAMTS13

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BILIRUBIN; CLOPIDOGREL; CORTICOSTEROID; CREATINE KINASE MB; CREATININE; FIBRIN DEGRADATION PRODUCT; HAPTOGLOBIN; HEMOGLOBIN; HEPARIN; LACTATE DEHYDROGENASE; OMEPRAZOLE; RITUXIMAB; TROPONIN T; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABNORMAL LABORATORY RESULT; ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; AGED; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD EXAMINATION; BRAIN INFARCTION; CASE REPORT; COLON CANCER; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG TREATMENT FAILURE; ELECTROCARDIOGRAM; EMERGENCY CARE; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY INJURY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MALE; MULTIPLE ORGAN FAILURE; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PLASMA EXCHANGE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; ACUTE DISEASE; COMPLICATION; MYOCARDIAL INFARCTION; THROMBOSIS; VERY ELDERLY;

ACUTE DISEASE; AGED, 80 AND OVER; HUMANS; MALE; MYOCARDIAL INFARCTION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOSIS;

EID: 84954349995     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000513     Document Type: Article

References (19)

1. Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K. Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol 2002; 75:25-34.
2. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589-600.
3. Patschan D, Witzke O, Dührsen U, Erbel R, Philipp T, Herget-Rosenthal S. Acute myocardial infarction in thrombotic microangiopathies: clinical characteristics, risk factors and outcome. Nephrol Dial Transplant 2006; 21:1549-1554.
4. Doll JA, Kelly JP. ST-segment elevation myocardial infarction treated with thrombolytic therapy in a patient with thrombotic thrombocytopenic purpura. J Thromb Thrombolysis 2014; 38:124-126.
5. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 2003; 127:834-839.
6. Gandhi K, Aronow WS, Desai H, Amin H, Sharma M, Lai HM, et al. Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience. Clin Cardiol 2010; 33:213-216.
7. Gami AS, Hayman SR, Grande JP, Garovic VD. Incidence and prognosis of acute heart failure in the thrombotic microangiopathies. Am J Med 2005; 118:544-547.
8. McCarthy LJ, Danielson CF, Skipworth EM, Peters SL, Miraglia CC, Antony AC. Myocardial infarction/injury is relatively common at presentation of acute thrombotic thrombocytopenic purpura: the Indiana University experience. Ther Apher 2002; 6:2-4.
9. Perez L, Ramappa P, Guzman JA. Myocardial injury in thrombotic thrombocytopenic purpura: a frequent, perplexing complication. Int J Cardiol 2007; 128:257-260.
10. Hawkins BM, Abu-Fadel M, Vesely SK, George JN. Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion 2008; 48:382-392.
11. Tobbia P, Brodie BR, Witzenbichler B, Metzger C, Guagliumi G, Yu J, et al. Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. EuroIntervention 2013; 8:1134-1142.
12. Wi J, Ko YG, Shin DH, Kim JS, Kim BK, Choi D, et al. Prediction of contrast-induced nephropathy with persistent renal dysfunction and adverse long-term outcomes in patients with acute myocardial infarction using the Mehran risk score. Clin Cardiol 2013; 36:46-53.
13. Matsuo T, Tomaru T, Kario K, Hirokawa T, HIT Research Group of Japan. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome. Thromb Res 2005; 115:475-481.
14. Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012; 38:845-853.
15. Zakarija A, Kwaan HC, Moake JL, Bandarenko N, Pandey DK, McKoy JM, et al. Ticlopidine-and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int 2009; 112:S20-S24.
16. Zakarija A, Bandarenko N, Pandey DK, Auerbach A, Raisch DW, Kim B, et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004; 35: 533-537.
17. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med 2010; 49:7-15.
18. George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (Experience of The Oklahoma TTP-HUS Registry, 1989-2007). Kidney Int 2009; 112: S8-S10.
19. Francis KK, Kalyanam N, Terrell DR, Vesely SK, George JN. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases. Oncologist 2007; 12:11-19.